Ghrelin inhibits cisplatin‑induced MDA‑MB‑231 breast cancer cell apoptosis via PI3K/Akt/mTOR signaling

  • Zhang J
  • Xie T
N/ACitations
Citations of this article
21Readers
Mendeley users who have this article in their library.

Abstract

Ghrelin is a multi-functional peptide, its role on cancer cell apoptosis remains controversial. The present study examined the effects and mechanisms of ghrelin on cisplatin-induced apoptosis in human breast cancer cells. It was identified that ghrelin inhibited apoptosis in MDA-MB-231 cells in vitro and reversed the expression of B-cell lymphoma 2 (Bcl2) and Bcl2-associated X, and cleaved caspase-3 induced by cisplatin. Furthermore, ghrelin activated the phosphoinositide 3-kinases/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway after cisplatin treatment. The effects of ghrelin on the cisplatin-induced apoptosis and PI3K/Akt/mTOR signaling were reversed by the growth hormone secretagogue receptor small interfering RNA. The present study suggests that ghrelin may serve as a novel target for cisplatin resistance and a potential indicator of cisplatin sensitivity in breast cancer treatment.

Cite

CITATION STYLE

APA

Zhang, J., & Xie, T. (2019). Ghrelin inhibits cisplatin‑induced MDA‑MB‑231 breast cancer cell apoptosis via PI3K/Akt/mTOR signaling. Experimental and Therapeutic Medicine. https://doi.org/10.3892/etm.2019.8398

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free